A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

NCT02269735 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: MK-2640
BIOLOGICAL: Regular Human Insulin (RHI)
DRUG: Dextrose
BIOLOGICAL: Insulin aspart
DRUG: Rescue medication

Sponsor

Merck Sharp & Dohme LLC